A UNIQUE OPPORTUNITY IN ANIMAL HEALTH JANUARY 2017
DISCLAIMER This document has been prepared by Gour Medical SA (“the Company”) solely for use at this presentation. By receiving this presentation, you acknowledge that you have read the following restrictions. This document is confidential and is not to be reproduced by any person, nor to be distributed. Certain information contained in this presentation includes forward-looking statements. Forward-looking statements are not guarantees of future performance of Gour Medical SA and its actual financial condition, actual results of operations and cash flows and the development of the industry in which it operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if Gour Medical SA’s financial condition, results of operations and cash flows and the development of the industry in which Gour Medical SA operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. Gour Medical does not undertake, nor does it have any obligation, to provide updates or to revise any forward-looking statements to reflect events that occur or circumstances that arise after the date of this presentation. Gour Medical takes no responsibility for the use of this information by any person. The information contained in this presentation has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The information set out herein is subject to updating, completion, revision, verification and amendment and such information may change materially. Gour Medical is under no obligation to keep current the information contained in this presentation and any opinion expressed in them is subject to change without notice. Gour Medical shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its contents or otherwise arising in connection with this document. It is not the purpose of this presentation to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of Gour Medical’s financial or commercial position or prospects. This document does not constitute an offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares of Gour Medical in the United States or any other jurisdiction and nor any part of it shall form the basis of, or be relied upon in connection with, any contract, commitment or investment decision in relation thereto. In France , the offer of Gour Medical’s shares described above will take place solely as a private placement, in accordance with Article L. 411-2 of the Code monétaire et financier and applicable regulations. The offering does not constitute a public offering in France, as defined in Article L. 411-1 of the Code monétaire et financier and no prospectus reviewed or approved by the Autorité des marchés financiers will be published. The Company’s securities have not been, and will not be, registered under the United States Securities Act 1933 (the “Securities Act”), nor with any market authority within the United States. Therefore, the Company’s securities can not be offered, sold, distributed or otherwise transferred within the United States, nor on behalf of or for the benefit of U.S. persons except pursuant to an exemption from the registration requirements under the Securities Act or a registration under the Securities Act. This Presentation can not be distributed or transferred by anyone within the United States. In the United Kingdom , this presentation is directed only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Financial Promotion Order”), (ii) are persons falling within Articles 49(2 )(a) to (d) (“High Net Worth Companies, Unincorporated Associations, etc ”) of the Financial Promotion Order, (iii) are persons to whom an invitation or inducement to engage in investment activity ( within the meaning of Section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any shares may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”). This presentation is directed only at Relev ant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This presentation is solely for your information on a confidential basis and may not be reproduced, redistributed or published (whether internally or externally to your company), directly or indirectly, in whole or in part, to any other person. Neither this document nor any copy of it may be taken, transmitted into or distributed in the United States of America, Canada, Australia, Japan or to any resident of these countries. The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities law. 2
ADVANCED CARE FOR MATURE PETS OUR MISSION GOUR Medical offers veterinarians a new way to support mature pets and their owners, with products designed for the specific needs of the older pet The range of products will address specific conditions and enable mature pets to benefit from the most advanced scientific innovations GOUR Medical makes it possible by investing in human-based R&D transferred to animal health 3
A GROWING MARKET WITH LARGE POTENTIAL FOR GOUR OFFER Turnover in 2014 / Estimates in USD Bn (worldwide) 40 23.4 20 9.4 3.5 1 0 Total Companion Mature GOUR Animal Animals Pets potential Health conditions market 4 Source : ERS - Healthcare Innovation – July 2015
WHY INVEST IN ANIMAL HEALTH ? Companion animals (CA) potential market (USD Bn) worldwide 16 13.5 14 CAGR* +6,2% 12 9.4 10 9 8 6 4 2 0 Turnover CA 2013 Turnover CA 2014 Turnover CA 2020 Source Jefferies International Limited – June 2015 5 * Cumulative Annual Growth Rate (CAGR)
WHY INVESTING IN GOUR MEDICAL ? Mature pets 30% of total worldwide pets population* • Mature pets require specific and regular medical care, as disease prevalence and chronic pathologies are higher in this population Potential mature pets market for GOUR medical offer : USD 1 Bn 6 *Source Aurgalys
OUR STRATEGIC POSITIONNING GOUR IS UNIQUE BY COMBINING INNOVATION AND MATURE PETS TARGET 7
OUR BUSINESS MODEL ACQUISITION OF EXCLUSIVE LICENSES AND DISTRIBUTION RIGHTS FROM LEADING TECHNOLOGY PROVIDERS Looking for innovative solutions to improve mature pets’ health and life License molecules through third parties Develop products up to market readiness alone or with external partners Commercialize products through external partners 8
A BALANCED PRODUCT PIPELINE POC: proof-of-concept GOUR-153:Pain / GOUR-713:Anxiety / GOUR 419:Atopy 9
GO TO MARKET Gour medical will sell to veterinary professionals via partnerships with distributors and animal health companies Control of distribution costs Key countries at launch period will be: France, UK, Germany, Italy and Spain 10
HIGH QUALITY OPHTHALMIC LINE TO CLEAN AND LUBRICATE EYES GOUR peak annual sales : > 3 M EUR NEXT STEPS: Re-confirm regulatory status in selected countries before products launch Develop branding Select commercial partners starting with France and UK as a first step Examples only 11
GOUR-153 CANNABINOID BASED (CBD) TO SUPPORT ANIMALS SUFFERING FROM PAIN GOUR peak annual sales : > 10 M EUR NEXT STEPS: Compile submission and submit to EC Commission and the European Food Safety Authority Ensure a consistent purity of the product in agreement with standards for registration as feed additive 12
GOUR-713 DUAL RECEPTOR ANTAGONIST TO TREAT BEHAVIOR DISORDERS AND ANXIETY GOUR-713 peak annual sales : > 13 M EUR NEXT STEPS: Based on product profile, support the proof-of-concept work with regulatory input Assess targeted claim of Gour-713 on canine behaviour in laboratory and clinical studies 13
GOUR- 419 ANTI- IgE ANTIBODY TO TREAT ATOPIC DERMATITIS IN DOGS GOUR peak annual sales : > 60 M EUR NEXT STEPS: Confirm source of clinical material Obtain scientific advice on POC study design Day - 30 Produce material for POC study Day 53 14
DEVELOPMENT STRATEGY ACQUISITION OF NEW PRODUCTS Targeted therapeutics areas: Eyes and ears (dog and cat) Orthopedic disorders (dog and cat) Behavioral disorders (dog and cat) Dental disease (dog and cat) Cardiac diseases (dog) Kidney disease/failure (cat) … 15
Recommend
More recommend
